Antiverse vs Nabla Bio (2026)
These two picked the same fight. Both design antibodies against the hardest target class there is, G protein coupled receptors and ion channels, proteins that sit in the cell membrane and resist the usual discovery routes. The difference is scale and method. Antiverse is the small independent in Cardiff, pairing machine learning with its own cell line engineering, working on a fraction of the money its larger neighbors raise. Nabla Bio comes at the same targets with JAM, a generative system that completes an antibody from a target and an epitope, and it publishes its hit rates target by target along with the targets it missed. It has raised more and signed collaborations with AstraZeneca, Bristol Myers Squibb and Takeda. Antiverse is worth a look for a team that values a focused independent on hard targets. Nabla is the one when published, target by target evidence on membrane proteins is what a decision rests on.
- A focused independent chasing GPCRs and ion channels, pairing machine learning with its own cell line engineering.
- A smaller, leaner outfit for teams that prefer a dedicated partner over a large platform.
- Long standing attention to the membrane protein problem, with training data the company says it has built since 2017.
- Generative de novo design through JAM against the same membrane target class.
- Hit rates published target by target, including where the model produced no binder.
- Collaborations with three large pharmaceutical companies against the platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Antiverse and Nabla Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Antiverse | Nabla Bio |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2017 | 2021 |
| Headquarters | Cardiff, Wales, United Kingdom | Cambridge, Massachusetts, United States |
| Website | antiverse.io | nabla.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Antiverse its top capability grade on AI Centrality. Set against Nabla Bio, Antiverse does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against Antiverse, Nabla Bio grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose Antiverse or Nabla Bio?
The AI Health Index grades Nabla Bio higher than Antiverse on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Antiverse does not grade higher on any scored axis.
Where do Antiverse and Nabla Bio differ most?
The widest separation the AI Health Index records between Antiverse and Nabla Bio is on AI Governance and Bias Disclosure, where Antiverse grades D and Nabla Bio grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Antiverse and Nabla Bio grade the same?
The AI Health Index grades Antiverse and Nabla Bio the same on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Antiverse and Nabla Bio not disclosed?
At the last review, at least one of Antiverse and Nabla Bio published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Neither publishes a price, and both work through partnerships, with Antiverse operating on a far smaller funding base.
Ask both for the specific membrane targets they have produced binders against, and how they report the attempts that failed alongside the ones that worked.